MOTOLA, DOMENICO
MOTOLA, DOMENICO
DIMEC - DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Docenti di ruolo di IIa fascia
Comparative Safety Profiles of Biosimilars vs. Originators Used in Rheumatology: A Pharmacovigilance Analysis of the EudraVigilance Database
2025 Nikitina, Victoria; Laurini, Greta Santi; Montanaro, Nicola; Motola, Domenico
Overview of Orphan Medicines in European Union: An Analysis of Regulatory and Technical-Scientific Aspects
2025 Santi Laurini, Greta; Nikitina, Victoria; Broccoli, Massimiliano; Montanaro, Nicola; Motola, Domenico
Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab
2025 Nikitina, Victoria; Santi Laurini, Greta; Montanaro, Nicola; Motola, Domenico
Safety of Proton Pump Inhibitor in Paediatrics: A Study Based on EudraVigilance Data
2025 Santi Laurini, Greta; Nikitina, Victoria; Montanaro, Nicola; Motola, Domenico
PAttern of drug use in PEdiatrics: An observational study in Italian hOSpitals (the PAPEOS study)
2024 Di Salvo, M.; Santi Laurini, G.; Motola, D.; Valpiani, G.; Sapigni, E.; Pompilio, A.; Arzenton, E.; Marra, A.
Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database
2024 Nikitina, V.; Santi Laurini, G.; Montanaro, N.; Motola, D.
Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database
2023 Nikitina, Victoria; Santi Laurini, Greta; Montanaro, Nicola; Motola, Domenico
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database
2023 Santi Laurini G.; Montanaro N.; Broccoli M.; Bonaldo G.; Motola D.
Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis
2023 Santi Laurini G.; Montanaro N.; Motola D.
Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
2023 Santi Laurini G.; Montanaro N.; Motola D.
Safety profile of paediatric COVID-19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System
2023 Nikitina V.; Santi Laurini G.; Montanaro N.; Motola D.
Level of therapeutic innovation from the registration studies of the new drugs for the prophylaxis of migraine
2022 Motola D.; Santi Laurini G.; Bonaldo G.; Montanaro N.
Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data
2022 Motola D.; Bonaldo G.; Montanaro N.
Adverse event reporting with immune checkpoint inhibitors in older patients: Age subgroup disproportionality analysis in vigibase
2021 Noseda R.; Bonaldo G.; Motola D.; Stathis A.; Ceschi A.
Human papilloma virus vaccination in males: A pharmacovigilance study on the Vaccine Adverse Event Reporting System
2021 Bonaldo G.; Montanaro N.; Vaccheri A.; Motola D.
On criteria to evaluate the therapeutic innovation of drugs
2021 Motola D.; Montanaro N.
Removal of the EMA orphan designation upon request of the sponsor: cui prodest?
2021 Montanaro N.; Bonaldo G.; Motola D.
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
2021 Bonaldo G.; Montanaro N.; AlbertoVaccheri; Motola D.
Direct-acting oral anticoagulants and alopecia: The valuable support of postmarketing data
2020 Bonaldo G.; Vaccheri A.; Motola D.
Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization’s database
2020 Bonaldo G.; Vaccheri A.; Melis M.; Motola D.